TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06406205
Drug: Voclosporin（QL1074）
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.
Study: NCT06222476
Drug: Dorzagliatin
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzagliatin will be initiated and maintained at 75mg twice a day
Study: NCT06222476
Drug: Gliclazide
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide will be initiated and maintained at 30mg once a day
Study: NCT06142201
Drug: JT001
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral administration
Study: NCT05435573
Drug: 250 mL 6% hydroxyethyl starch (Voluven) then 500 mL of ringer's acetate solution then 250 mL of 6% hydroxyethyl starch (Voluven)
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride plus 500 mL of ringer's acetate solution
Study: NCT04989257
Drug: Ticagrelor-based dual-antiplatelet therapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin with ticagrelor
Study: NCT04989257
Drug: Clopidogrel-based dual-antiplatelet therapy
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Aspirin with clopidogrel
Study: NCT06439758
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1000 mg/day for 6 months
Study: NCT06205290
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT06205290
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT06205290
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06205290
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05855629
Drug: Topical Adapalene, Benzoyl Peroxide Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adapalene 1mg/g, Benzoyl Peroxide 25mg/ml
Study: NCT05264805
Drug: 0.25% Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
Study: NCT05234346
Drug: 150 mg 5-ALAPhosphate + SFC
Normalized name: Isopropyl fluophosphate
DrugBank: Isoflurophate (DB00677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
Study: NCT06293417
Drug: Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment group
Study: NCT06119659
Drug: Low dose KL001
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be dosed with single dose of KL001 at 2.5x10\^12 vg/kg.
Study: NCT06119659
Drug: Middle dose KL001
Normalized name: WHEAT MIDDLINGS
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with single dose of KL001 at 5.0x10\^12 vg/kg.
Study: NCT06119659
Drug: High dose KL001
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with single dose of KL001 at 1.0x10\^13 vg/kg.
Study: NCT05768503
Drug: Control Rx
Normalized name: Control Rx
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
Study: NCT05249725
Drug: Irsogladine Maleate
Normalized name: maleate
DrugBank: Irsogladine (DB13056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administration of irsogladine maleate 4mg/day, for 8 weeks.
Study: NCT05249725
Drug: Hydrotalcite
Normalized name: Hydrotalcite
DrugBank: Hydrotalcite (DB13322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were given 1 g hydrotalcite every morning, afternoon and evening for 8 weeks.
Study: NCT06431620
Drug: Recombinant Human Thyroid Stimulating Hormone
Normalized name: Recombinant Human Thyroid Stimulating Hormone
DrugBank: Thyrotropin alfa (DB00024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.
Study: NCT03938701
Drug: Adalimumab-800CW
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging
Study: NCT06429306
Drug: Dexycu
Normalized name: Dexycu
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
Study: NCT06572514
Drug: immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
Study: NCT04902105
Drug: ecopipam HCL
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT04902105
Drug: Divalproex Sodium ER
Normalized name: Divalproex Sodium ER
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablets
Study: NCT06661980
Drug: Dexmedetomidine Injectable Solution
Normalized name: dexmedetomidine Injectable Solution
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 200 mcg/ 2 mL IV.
Study: NCT06663254
Drug: Hydroxyethyl starch 130/0.4
Normalized name: Hydroxyethyl starch 130/0.4
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized goal-directed administration of 6% Hydroxyethyl starch (HES) 130/0.4: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min. If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. If the use of HES exceeds 30 ml/kg, sodium acetate Ringer will be replaced. In addition, patients will have a background infusion of sodium acetate Ringer's solution at 4 ml/kg/h to satisfy the maintenance fluid requirements during surgery.
Study: NCT06663254
Drug: Sodium acetate Ringer
Normalized name: Sodium Acetate
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized goal-directed administration of crystalloid alone: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min.~If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. In addition, patients will have a background infusion of sodium acetate, the maintenance fluid requirement during surgery.
Study: NCT06664008
Drug: PPI (proton pump inhibitor)
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: It reduces stomach acid production and manage GERD symptoms
Study: NCT06664008
Drug: Probiotic
Normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live microorganisms, primarily bacteria and yeast, that are believed to provide health benefits when consumed in adequate.
Study: NCT05063734
Drug: THR-687 dose level 1
Normalized name: Thr
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 intravitreal injections of THR-687 dose level 1, 1 month apart
Study: NCT05063734
Drug: THR-687 dose level 2
Normalized name: Thr
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 intravitreal injections of THR-687 dose level 2, 1 month apart
Study: NCT05063734
Drug: THR-687 selected dose level
Normalized name: Thr
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 intravitreal injections of THR-687 selected dose level, 1 month apart, possibly followed by a 4th intravitreal injection with the same dose level of THR-687 at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
Study: NCT05063734
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 intravitreal injections of aflibercept, 1 month apart, possibly followed by a 4th intravitreal injection with aflibercept at Month 3, or Month 4, or Month 5, if any of the PRN criteria are met.
Study: NCT00001022
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001022
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001022
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04317300
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.
Study: NCT04372615
Drug: Inebilizumab
Normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RCP: Blinded treatment on Day 1, Day 15,~* Inebilizumab group: Inebilizumab 300 mg intravenous (IV)~* Placebo group: IV matching placebo Prior to enrollment, all participants will receive standard of care, including high-dose corticosteroids (minimum of 3 days of treatment, 1 g methylprednisolone daily or equivalent) AND either IVIg (total dose range between 1.2 and 2 g/kg) OR plasmapheresis (defined as 5 or 6 exchanges).~Rescue therapy will be given to participants in either treatment group based on the results of the Week 6 assessments. Rescue therapy is cyclophosphamide 750 mg/m2 IV followed by additional doses every 28-30 days until the mRS score is ≤ 3 (at site Principal Investigator's discretion under standard of care).
Study: NCT00021307
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00021307
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04666649
Drug: Venetoclax and pegcrisantaspase
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Therapeutic
Study: NCT05044234
Drug: Cedirogant
Normalized name: Cedirogant
DrugBank: Cedirogant (DB18951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral
Study: NCT03292822
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: chemotherapeutic drug
Study: NCT04901117
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use according to the drug combination options selected by each center.
Study: NCT04901117
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use according to the drug combination options selected by each center.
Study: NCT04901117
Drug: Bismuth Potassium Citrate
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use according to the drug combination options selected by each center.
Study: NCT04901117
Drug: Colloidal Bismuth Pectin
Normalized name: bismuth / pectin
DrugBank: Pectin (DB11158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use according to the drug combination options selected by each center.
Study: NCT04901117
Drug: Vonoprazan fumarate
Normalized name: Vonoprazan fumarate
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Use according to the drug combination options selected by each center.
Study: NCT00507052
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06481150
Drug: Tenapanor
Normalized name: Tenapanor
DrugBank: Tenapanor (DB11761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each tablet 30 mg
Study: NCT05217914
Drug: Copanlisib (BAY80-6946)
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copanlisib for treatment of relapse/refractory (r/r) indolent non-Hodgkin lymphoma (iNHL)
Study: NCT06208488
Drug: Gefurulimab PFS-SD
Normalized name: Alphanine SD
DrugBank: Gefurulimab (DB18928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.
Study: NCT06208488
Drug: Gefurulimab AI
Normalized name: Gefurulimab
DrugBank: Gefurulimab (DB18928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.
Study: NCT06571214
Drug: Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)
Normalized name: follitropin alfa Injection [Gonal F]
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.
Study: NCT06571214
Drug: Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)
Normalized name: lutropin alfa
DrugBank: Lutropin alfa (DB00044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.
Study: NCT04528563
Drug: Morphine Sulfate 10Mg/1mL Injection
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid commonly used for acute abdominal pain given intravenously.
Study: NCT05294263
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline is a selective nACHr partial agonist of the 4 2 subtype and a full agonist of the 7 subtype
Study: NCT06026566
Drug: Dos of Afentanil 20
Normalized name: alfentanil
DrugBank: Alfentanil (DB00802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the dosage of Afentanil is 20 ng/ml for TCI
Study: NCT06026566
Drug: Dos of Afentanil 30
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the dosage of Afentanil is 30 ng/ml for TCI
Study: NCT06026566
Drug: Dos of Afentanil 40
Normalized name: sodium bicarbonate 40 MG/ML [Neut brand of sodium bicarbonate]
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the dosage of Afentanil is 40 ng/ml for TCI
Study: NCT06026566
Drug: Dos of Afentanil 60
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the dosage of Afentanil is 60 ng/ml for TCI
Study: NCT06026566
Drug: Dos of Afentanil 70
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the dosage of Afentanil is 70 ng/ml for TCI
Study: NCT06026566
Drug: Dos of Afentanil 80
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the dosage of Afentanil is 80 ng/ml for TCI
Study: NCT06026566
Drug: Dos of Afentanil 90
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the dosage of Afentanil is 90 ng/ml for TCI
Study: NCT06026566
Drug: Dos of Afentanil 100
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the dosage of Afentanil is 100 ng/ml for TCI
Study: NCT04979221
Drug: Cyproheptadine
Normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine 8mg three times a day during 10 days
Study: NCT05590702
Drug: First line therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient with CLL or SLL requiring a therapeutic strategy according to iwCLL criteria or investigator evaluation will be identified in MCM (multidisciplinary collegial meeting).~Patients will be treated and managed according to the decision of their physicians and the related MDM. No treatment plan is recommended in the setting of this non-interventional study.
Study: NCT06573957
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient in experimental arms will received intravenous dexmedetomidine at a dose of 0.5 µg/kg body weight 10 minutes before general anesthesia induction
Study: NCT06573957
Drug: Lidocain
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient in experimental arms will receive intravenous lidocaine at 1.5 mg/kg body weight in a 5cc syringe 90 seconds before intubation
Study: NCT05889624
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During an 8-week active treatment, participants will begin taking a daily pill (amitriptyline) prescribed and managed clinically by the site headache provider. Amitriptyline will be taken once a day before bedtime. The weight based dosage will gradually be increased based on tolerability and a standardized titration protocol during the 8 week active treatment. The participant will remain on a maximum tolerated dose for the final 16 weeks (maintenance).
Study: NCT03559686
Drug: Certolizumab Pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The recommended maintenance dose of Cimzia® (Certolizumab Pegol) for adult patients with Rheumatoid Arthritis (RA) is 200 mg every 2 weeks (single 1 mL injection of 200 mg) .
Study: NCT05798507
Drug: Avutometinib
Normalized name: Avutometinib
DrugBank: Avutometinib (DB15254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05798507
Drug: Defactinib
Normalized name: Defactinib
DrugBank: Defactinib (DB12282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03532516
Drug: Brivaracetam
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will start on the individual Brivaracetam (BRV) dose that they had reached at the completion of the previous study. The BRV dose can be adjusted based on the individual patient's seizure control and tolerability; however, the BRV dose may not exceed 200 mg/day in divided (preferably symmetrical) morning and evening doses, taken with or without food.~Up- and down-titration steps should be performed in steps of maximum 50 mg/day on a weekly basis. The full down-titration should include a 1-week step at 20 mg/day.
Study: NCT06369571
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10mg daily by mouth
Study: NCT06404177
Drug: Dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous perfusion of eunantyum with an intramuscular isotonic saline
Study: NCT05914584
Drug: Baricitinib 4 MG
Normalized name: baricitinib 4 MG
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reference drug
Study: NCT05596669
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: to examine the pain-relieving effects of ketamine vs ketamine magnesium infusion, as well as their influence on postoperative morphine consumption following nephrectomy; the secondary goal is to assess hemodynamic effects and pain severity
Study: NCT04978038
Drug: Prevnar13
Normalized name: Prevnar 20
DrugBank: Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer Prevnar-13 pneumococcal vaccine 0.5ml dose administered intramuscularly
Study: NCT04428632
Drug: Berotralstat
Normalized name: Berotralstat
DrugBank: Berotralstat (DB15982)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One 150mg capsule administered orally once daily
Study: NCT05187455
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Each patient received a single dose administration of sugammadex 2mg/kg at reappearance of the second twitch of the train-of-four (TOF).
Study: NCT05372198
Drug: Chohort 1: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 300mg, qd, every 3 weeks as a cycle
Study: NCT05372198
Drug: Chohort 2: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 250mg, qd, every 3 weeks as a cycle
Study: NCT05205603
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab, 5mg/kg at week 0,2,6 and schedule administration at every 8 weeks